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Abstract   
 
Background: Cystic fibrosis (CF) is the most common life-shortening autosomal 
recessive disease found among Caucasians. It is known to target many organs systems 
such as the lungs, liver, and intestines but the most affected organ is the respiratory tract. 
Patients with CF usually develop some type of pulmonary dysfunction resulting in 
frequent asthma-type exacerbations and chronic bacterial infections due to excessive 
mucus adhesion. Maintenance therapy with hypertonic saline (HS) has shown to be 
beneficial in helping with mucociliary clearance but compliance is low due to a high 
profile of side effects. Recent studies have shown that hyaluronic acid (HA) in addition to 
HS helps improve the tolerability of HS. The purpose of this review is to further evaluate 
the benefits of combination therapy on tolerability and efficacy in patients with CF.  
 
Methods: A comprehensive search of the medical literature was conducted using various 
search modalities including Medline/OVID, EBSCOhost/CINAHL, Web of Science, and 
Google scholar. Keywords used included: cystic fibrosis, hypertonic saline, and 
hyaluronic acid.  
 
Results: Three articles met the inclusion and exclusion criteria for this systematic review. 
All three articles were randomized control trials which showed a statistically significant 
improvement regarding tolerability with the addition of HA to HS.          
 
Conclusion: This systematic review provides evidence that supports the indication for 
combination therapy with HA to improve tolerability and efficacy of HS therapy alone in 
patients with CF. However, these results would be strengthened with larger and longer 
randomized controlled studies.     
 
Keywords: cystic fibrosis, hypertonic saline, hyaluronic acid 
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The Efficacy and Tolerability of the Combination of Inhaled Hypertonic Saline and 
Hyaluronic Acid versus Inhaled Hypertonic Saline in Patients with Cystic Fibrosis 
 
BACKGROUND  
 
 Cystic fibrosis (CF) is the most common life-shortening autosomal recessive 
genetic disorder found among caucasians.1 The disease involves various organ systems 
such as the lungs, liver, and intestines.2 The most affected organ system is the respiratory 
tract and lung disease which causes a 95% morbidity and mortality in patients with CF.3   
 CF is caused by a defect in the chloride-ion transport protein, CFTR, which 
functions as an apical epithelial chloride channel. Absence of CFTR results in failure to 
secrete Cl- and unrestrained Na+ absorption leading to the depletion of the airway surface 
fluid that covers airway epithelial cells.4 The depletion of airway surface liquid as well as 
consecutive breakdown of mucociliary transport ultimately causes excessive adhesion of 
mucus to airway surfaces.5 This retention of mucus is believed to favor bacterial 
overgrowth which triggers chronic infections and airway inflammation.4 There is some 
controversy about how the loss of CFTR function contributes to the pathogenesis of CF 
but several mechanisms have been proposed.3 However, it is known that patients with CF 
often acquire Pseudomonas aeruginosa infections that are frequently refractory to 
antimicrobial therapy. Therefore, regardless of antimicrobial therapy, CF airway 
infections are suppressed for short periods before reoccuring.6      
 The management of CF is based around chest physiotherapy to loosen and break 
up mucus, antibiotics to treat infections, pancreatic enzyme replacement, and careful 
monitoring of nutritional status.7 However, it is understood through previous studies that 
the inhalation of hypertonic saline (HS) increases mucociliary transport and improves 
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lung function.8 HS increases the NaCl concentration on airway surfaces resulting in 
increased absorption of Cl- in the paracellular path due to the absence of CFTR.9 This 
path has a slower rate of NaCl absorption compared to the normal Cl- channel used when 
the CFTR is functioning. The result is an increased retention of NaCl on airway surfaces 
and an osmotic gradient which favors water flow from the HS that persists for longer 
periods of time. In simpler terms, HS helps increase hydration of airway surface liquid by 
improving mucociliary clearance. The overall outcome is less mucus adhesion.10   
 However, a main issue with HS treatment is compliance due to the side effects 
patients with CF experience. Common complaints include increased cough, chest 
tightness, and throat irritation.11 Particularly in children, the salty taste of HS contributes 
to the lack of long term compliance and use.10    
 Hyaluronic acid (HA) has been used in lung disease to help prevent 
bronchoconstriction due to its hydration properties.12 A case study done in 2013 
involving a 13 year old Caucasian boy with CF who was experiencing recurrent 
wheezing and consistent asthma-type exacerbations despite treatment with maintenance 
therapy with HS. The patient was observed over a period of seven years while on 
treatment with HS+HA. The overall results with combination therapy showed a 
significant decrease of oral antibiotic administration, an elimination of the need for oral 
steroids, and an improvement in the frequency of pulmonary exacerbations this patient 
experienced.13 This study showed that the addition of HA to HS may improve tolerance 
to HS as well as results in stability of pulmonary function.      
 HA is a glycosaminoglycan whose function is to balance water homeostasis in the 
extracellular matrix. Many studies have been done in vitro and in vivo demonstrating the 
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potential benefits of HA by inhalation. One unique property of HA which is particularly 
useful is its water-retaining properties and the fact that the water content of a tissue 
depends on the amount of HA it contains.12 For these reasons, it is believed that the use 
of HA in lung disease such as CF will be beneficial in reducing the adverse effects of HS 
as well as decreasing poor compliance with therapy.   
 The goal of this study is to conduct a systematic review of the literature on 
patients with CF and to further evaluate the benefits of using combination therapy versus 
HS alone.  
 
METHODS 
 A comprehensive search of the medical literature was conducted using various 
search modalities including Medline/OVID, EBSCOhost/CINAHL, Web of Science, and 
Google scholar using the keywords “cystic fibrosis,” “hypertonic saline,” and “hyaluronic 
acid” individually or in combination. Inclusion criteria for this systematic review were 
publication dates from 2000-2014, English language studies on humans, and randomized 
controlled trials. Excluded from this review were case reports. The reviewed studies were 
critically appraised and assessed for quality using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE).14   
 
RESULTS 
 A total of three articles which met the inclusion and exclusion criteria were 
examined in this review (see Table I). The average sample size was approximately 29, 
 - 9 -  
with the largest group studied consisting of 40 patients with CF, and the smallest group 
consisting of 20. The shortest study lasted 2 days and the longest study lasted 28 days.  
All three articles2,15,16 included in this review were randomized, controlled studies. Of 
those three articles, two were double-blinded while the other used computer 
randomization. All studies looked at the benefit of using combined HA+HS versus HS in 
patients with CF.   
 
Ros et al 
 Ros et al,15 conducted in 2014, was a double-blinded, randomized controlled 
study that looked at the effects of using HS+HA versus HA alone during a four week 
treatment period. Participants were recruited from four Italian CF centers and were 
required to be at least 8 years old with a confirmed diagnosis of CF. Other inclusion 
criteria were the presence of clinically and therapeutically stable disease during the 
previous 30 days, a FEV1 > 50% of predicted value, and intolerance (cough, throat 
irritation, saltiness) to HS solution. Exclusion criteria included a decrease in FEV1 > 15% 
after HS, an infection with Burkholderia cepacia, infective exacerbation requiring 
antibiotics in previous 15 days, non compliance to standard therapy, a history of lung 
transplant, the inability to perform reproducible spirometry, intolerability to beta 2 
bronchodilators, current enrollment in other clinical trials, or having circulating plasmatic 
creatinine or transaminase levels higher than twice normal values.15    
 A total of 40 patients of both sexes, 10 participants per center were enrolled in the 
study and randomized to one of two treatment groups. The treatment groups consisted of 
20 patients to standard therapy with HS and 20 patients to HS+HA therapy. Before 
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starting treatment, qualified participants were given 200 µg of salbutamol. The test 
product (HA+HS or HS) was then administered with a nebulizer over approximately 15 
minutes. Spirometry was done three times: at time 0, then 15 minutes after salbutamol, 
and lastly 30 minutes after the test product. All participants were given 60 visually 
identical vials to be used twice a day for 28 days.  They were required to use salbutamol 
15 minutes prior to each treatment and to complete self-assessment cards every week. 
The last dose of treatment was given in hospital and spirometry was again performed 
three times as before. There were no significant differences in baseline characteristics and 
spirometric evaluation of patients between groups. There were five patients who did not 
complete the study, two from the HS+HA group and three from the HS group. Reasons 
for incompletion of the study included cough or throat irritation, and respiratory 
exacerbation.15  
 The primary outcome was to assess whether the combination product of HS+HA 
was better tolerated than HS alone in patients who had shown little tolerance to HS. 
Effects were evaluated based on cough, throat irritation, salty taste and overall 
acceptability using a semiquantitative scale on a diary card weekly. The secondary 
outcome evaluated the change in FEV1 at the end of treatment.15 
 The severity of cough, throat irritation, and saltiness decreased in patients treated 
with HS+HA compared to HS alone. In the group of patients who received HS+HA, 
symptoms of cough, throat irritation, and saltiness was milder (10%, 15%, and 10%) 
compared to HA alone (60%, 40%, and 60%). In addition to these values, the RRR for 
each symptom was 83%, 62%, and 83% respectively which shows a significant reduction 
when using combination therapy of HS+HA.15 
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 Although there was an increase in FEV1 in both groups after inhalation with 
salbutamol, there was no significant reduction in FEV1 with both treatments (HS+HA and 
HS alone). Furthermore, there was no significant difference of FEV1 between the two 
groups after 28 days treatment.15  
 
Funari et al 
 Funari et al,2 conducted in 2012, was a double-blinded, randomized controlled 
study that assessed the tolerability of HS when used in combination with HA over a 
period of 28 days. The study took place at the Regional Reference Centre for Cystic 
Fibrosis in Italy.  The inclusion criteria were male and female patients at least 10 years 
old, a clinical diagnosis of CF, a FEV1 at least 40% of predicted value, current stable 
antibiotic, mucolytic, or anti-inflammatory treatment in 3 months prior to the study, and 
provided informed consent. Exclusion criteria included any Burkholderia cepacia 
infection, HS therapy in the 15 days preceding enrollment, an exacerbation of infection in 
the 15 days before inclusion which required antibiotic therapy, or changes in chronic 
therapy in the 28 days before the enrollment period. Those who qualified for the study 
were immediately assessed after receiving treatment at their baseline visit. If treatment 
was not tolerated even after use of a beta 2 bronchodilator, they were dismissed from the 
study.2    
 A total of 30 patients of both sexes were enrolled in the study and randomized to 
one of two treatment groups: 15 patients to therapy with 7% HS and 15 patients to 
Hyaneb (HS+HA) therapy. Treatment consisted of one inhalation of the assigned product 
twice a day for 28 days to be done at home. A short-acting B2 bronchodilator was given 
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to the selected patients in case of bronchospasm which was recorded in patient diaries if 
used. They were allowed to continue with their usual treatment for lung disease or 
concomitant diseases as long as they were under such treatment during the time of the 
study inclusion. FEV1 was measured twice; before and one hour after inhalation of the 
assigned product. All patients were required to complete an evaluation questionnaire on 
tolerability and pleasantness of their assigned treatment weekly and log their results in a 
patient diary. There were no significant differences in demographic characteristics and 
spirometric evaluation between the two groups in this study. There was a total of one 
dropout which was from the baseline visit while two others did not complete their diaries 
and were omitted from the final results of the study (two participants from the HS group 
and one from the combination therapy group).2  
 The primary outcome was to assess whether the addition of HA improved the 
tolerability of HS in patients with CF. Effects were evaluated based on bronchospasm 
which was measured based on the amount of beta 2 agonists used and FEV1 before and 
after treatment. The secondary outcomes evaluated cough, irritation, thoracic 
constriction, saltiness, and efficacy of the combination product on pulmonary function.2 
 The use of beta 2 agonists was statistically significantly lower in the Hyaneb 
group versus the HS group (RRR= 60%, P<0.0001, 95% CI of -1.3 to -1.1). At the end of 
the study, two patients (14.3%) in the Hyaneb group required beta 2 agonists compared to 
the five (35.7%) in the HS group.2 There was a greater change in FEV1 at baseline before 
and after treatment in the HS group compared to the Hyaneb group (4.3 versus 2.2 
respectively). However, there was no significant difference in FEV1 before and after 
treatment at the end of 4 weeks.2 Analyzing the evaluation questionnaire confirmed the 
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positive benefits of HA on tolerability with statistically significant lower cough and 
throat irritation in the Hyaneb group (p=0.0010). At baseline, 14 patients (100%) in the 
Hyaneb group had no or light throat irritation compared to the 11 (73.3%) in the HS 
group. By week 4, there was 10 patients (71.4%) with no irritation, four (28.6%) with 
light irritation, and non with moderate throat irritation in the Hyaneb group compared to 
eight (61.5%) with no irritation, three (23.1%) with light irritation, and two (15.4%) with 
moderate irritation in the HS group.2 Overall pleasantness of treatment was significantly 
different (p<0.0001) in favour of the Hyaneb group. Most patients in the Hyaneb group 
(92.8-100%) reported an absence of taste or saltiness compared to 46.7%-69.3% of 
patients in the HS group reported absence of taste or a light salty taste.2          
 
Buonpensiero et al 
 Buonpensiero et al,16 conducted in 2010, was an open, randomized crossover trial 
which compared a single treatment of HS and a single treatment of HS+HA over a period 
of three days. Each treatment lasted one day with a washout period of one day inbetween. 
Allocation was concealed using an off-site investigator. Participants were recruited for 
one month from a regional pediatric CF center based on the following inclusion criteria 
of an established diagnosis of CF, an age of at least 6 years, a FEV1 of 50% or more of 
the predicted value, and a clinically stable lung disease. Exclusion criteria were evidence 
of reactive airway or a clinical diagnosis of asthma.16 
 A total of 20 patients of both sexes who routinely received HS were placed into 
treatment groups through computer randomization, ten received treatment with HS and 
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ten received treatment with HS+HA. A dose of salbutamol was administered 30 minutes 
before each assigned treatment.16  
 The primary outcome of this study was to the tolerability of HS and HS+HA due 
to cough. Effects were evaluated based on cough, throat irritation, and salty taste using a 
four-point ordinal scale after each treatment. Results were recorded on a diary card.  The 
secondary outcomes evaluated lung function testing and overall pleasantness. FEV1 was 
measured using spirometry before and after each treatment while overall pleasantness 
was assessed using a Likert-type scale.16   
 There was a statistically significant difference between treatment groups 
regarding the measurement of cough, throat irritation, and saltiness (P<0.05).16 The 
treatment group who received HS+HA rated the severity of cough 0 (absent) while the 
group receiving HS rated the severity 2 (moderate). Cough immediately after inhalation 
of HS occurred in 18 of 20 participants (90%) while after inhalation with HS+HA, cough 
occurred in only 7 of 20 participants (35%). There was a statistically significant reduction 
of cough with the addition of HA demonstrated by a RRR of 61% and an ARR of 55% 
(95% CI: 25%, 73%).16 There was a significant reduction in prevalence of throat irritation 
with the combination treatment shown by ratings of 0 (absent) compared with ratings of 1 
(mild) in patients treated with HS alone. Throat irritation immediately after inhalation of 
HS occurred in 14 of 20 participants (70%) while after inhalation with HS+HA, throat 
irritation occurred in only 1 of 20 participants (5%). Statistically, the RRR for throat 
irritation was 93% and the ARR was 65% (95% CI: 36%, 81%).16 The ratings for severity 
of salty taste was 0 (absent) in the combination treatment group and 2 (moderate) in the 
HS group. A salty taste immediately after inhalation of HS occurred in all participants 
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(100%) while after inhalation with HS+HA, a salty taste occurred in only 2 of 20 
participants (10%). The RRR for the prevalence of salty taste was 90% and the ARR was 
90% (95% CI: 64%, 97%), which once again shows a significant reduction when using 
combination therapy of HS+HA.16 For overall pleasantness, the ratings for the 
combination treatment group was 0 (absent) and 2 (moderate) for treatment with HS. 
There was a statistically significant reduction in unpleasant taste with the addition of HA 
shown by a p value < 0.05.16   
 The values of FEV1 were identical in both treatment groups of HS or HS+HA 
preinhalation and postinhalation. There were no statistically significant differences or 
changes regarding lung function based on spirometry.16 
 
DISCUSSION 
 Pulmonary complications are highly probable in patients with CF since the 
respiratory tract is the most affected organ.3 The main purpose of using inhaled HS in 
patients with CF is to improve mucociliary clearance and overall lung function.  The 
benefit of HS is that it increases hydration of airway surfaces but at the same time, it is 
difficult to tolerate due to side effects such as unpleasant taste, increased cough, and 
airway irritation.10 Some research has shown that with the addition of HA to HS, 
tolerability and efficacy has improved.   
 This systematic review evaluated three studies2,15,16 which assessed the benefit of 
using combination therapy (HS+HA) versus HA alone and how this change affected 
tolerability and efficacy. All three studies demonstrated positive effects in regards to 
tolerability when using combination therapy in patients with CF (See Table II). 
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Specifically, Ros et al15 demonstrated a statistically significant overall improvement in 
severity of cough, throat irritation, and saltiness with combination therapy with RRR 
values of 83%, 62%, and 83% respectively. Furthermore these findings were consistent 
with the Funari et al2 study which showed a statistically significant improvement of 
saltiness with combination therapy versus HS alone (p < 0.0001). Moreover, there was a 
statistically significant decrease in cough and thoracic constriction with combination 
therapy which was evaluated by usage of a beta 2 bronchodilator (RRR=60%) and 
spirometry. There was improvement of airway irritation in the HS+HA group versus HS 
group. The combination therapy group showed an increased tolerability with use of a 
five-point scale by scoring the study as acceptable whereas the HS group scored the study 
as disgusting and unpleasant.2 The last study by Buonpensiero et al16 also evaluated for 
cough, throat irritation, and salty taste.  The addition of HA showed a statistically 
significant reduction in all outcomes (RRR of 61%, 93%, 90% respectively) and 
statistically significant improvement in pleasantness (p<0.05). However, there was no 
significant improvement in pulmonary function measured by FEV1 in any of the studies 
with the two different treatments. This lack of significance is mostly due to the duration 
of the studies being less than several months. 
  There was little risk of bias in these three studies since two were double-blinded 
randomized controlled studies while the third was a randomized crossover trial which 
used computerized randomization and allocation was concealed using an off site 
investigator. The major limitations of these studies included cohort size and length of 
study. The small sample size of the three studies (< 40 subjects) limits the precision of 
estimating the benefit of combination therapy in patients with CF ultimately 
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compromising validity. The short duration of exposure (< 28 days) for the three studies 
limits the boundaries of safety regarding long term treatment with combination therapy. 
Assessment for quality of each study were done using the GRADE assessment tool which 
is shown in Table I.14     
 Based on the results of the most current studies presented here, further studies are 
warranted. Future studies should follow the format of the literature presented here with 
randomized, controlled, blinded studies. There should be an improvement in validity by 
recruiting a larger cohort of participants and holding the clinical trial for longer durations 
of time. The benefit of increasing the length of time for follow-up of patients will give 
insight into whether or not lung function would respond to this therapeutic response. 
Future studies should consider evaluating the effects of HS+HA on mucus production 
since the literature so far assesses only tolerability and pleasantness. Furthermore, studies 
involving a younger set of patients in order to evaluate whether or not HS+HA 
combination therapy can protect lung function would be worthwhile. It would also be a 
good idea to consider addressing the cost-effectiveness of HS+HA as an alternative to 
other mucolytic therapies.16           
 
CONCLUSION 
 Pulmonary dysfunction continues to be one of the most troublesome problems 
that patients with CF have to endure. Chronic bacterial infections and recurrent asthma-
type exacerbations contribute to lung disease which can lead to death if not treated. 
Maintenance therapy with inhaled HS has been used but due to its high profile of side 
effects, compliance with treatment is low.4 The results from this systematic review 
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provides evidence that HA significantly improves the tolerability and efficacy of HS. 
This combination therapy has shown to reduce salty taste, cough, airway irritation, and 
bronchoconstriction; all common side effects of treatment with HS alone in patients with 
CF.2,15,16 There has been sufficient evidence to support the indication for combination 
therapy of HS+HA as an alternative mucolytic agent in patients with CF not only to 
reduce the amount of side effects from HS alone, but to improve quality of life.  
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TABLE I:  Characteristics of Reviewed Studies 
a
 Small sample size  
b
 Short study duration of 3 days 
 
 
 
 
 
  
Quality Assessment  
 Downgrade Criteria 
Quality 
Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Ros et al15  
RCT  Not 
serious  Not serious Serious
a Not serious No bias likely Moderate 
Funari et al2  
RCT  Not serious Not serious Seriousa Not serious No bias likely Moderate 
Buonpensiero et al16  
RCT Seriousb Not serious Seriousa Not serious No bias likely Low 
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TABLE II:  Summary of Findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Number of Patients  Outcomes 
Study Treatment (total) 
Placebo or 
no treatment 
(total) 
Improved overall 
tolerability/pleasantness 
(P value) 
Cough 
(RRR/ARR) 
Throat 
irritation 
(RRR/ARR) 
Saltiness 
(RRR/ARR) FEV1 
Ros et al15 20 20 <0.0001 83%/--- 
 
 
62%/--- 
 
 
83%/--- 
 
No 
significant 
improvem
ent 
Funari et al2 27 14  60% 
  
 
 
No 
significant 
improvem
ent 
Buonpensiero 
et al16 20 20 <0.05 61%/55% 
 
  
93%/65% 
 
 
90%/90% 
 
No 
significant 
improvem
ent 
